Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.
ValenzaBio plans to use the new financing to advance pipeline programs into autoantibody-mediated diseases, thyroid eye disease, inflammatory disorders and other therapeutic areas.
The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.
Eleven months after launching with $60 million in hand, Ventus Therapeutics has raised another $100 million to drive its pipeline toward the clinic.
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis.
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.